A Meta‐Analysis of Pain Response in the Treatment of Fibromyalgia
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Objective: This meta‐analysis compared efficacy (pain response) of drugs that are licensed or commonly used in the treatment of fibromyalgia. A meta‐analysis of safety measured via discontinuation because of adverse events was also performed. Methods: We conducted a meta‐analysis of 21 clinical trials to estimate treatment differences vs. placebo, separately, for duloxetine, fluoxetine, gabapentin, milnacipran, pramipexole, pregabalin, either of two tricyclic antidepressants, and tramadol plus paracetamol. Indirect treatment comparisons using mixed treatment comparisons methodology were conducted for all pairwise comparisons. Pain response was analyzed as improvement of at least 30%, and separately of 50%, from baseline. Results: When compared with placebo, statistically significant pain responses (improvement of 30% and 50%) were observed for patients treated with duloxetine, milnacipran 200 mg/day, pregabalin 300 or 450 mg/day, and tramadol plus paracetamol. Treatment with fluoxetine, gabapentin, or milnacipran 100 mg/day resulted in significant findings for the 30% improvement in pain response. The meta‐analysis showed a statistically increased risk of discontinuation because of adverse events for milnacipran 100 and 200 mg/day (both P < 0.001), and pregabalin 300 and 450 mg/day (P = 0.009 and P < 0.001, respectively). All other treatments, except fluoxetine, showed numerically increased risk over placebo for discontinuation because of adverse events. In the indirect comparisons, no pairwise comparison of active treatments reached statistical significance for either pain response end point. Conclusion: All eight active treatments displayed evidence suggesting improvement over placebo in the treatment of pain in patients suffering from fibromyalgia. Indirect comparison of active treatments found no strong differences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bucher, H. C., Guyatt, G. H., Griffith, L. E., & Walter, S. D. (1997) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(97)00049-8 · Cited by 2,052
Meta‐Analysis Of Controlled Clinical Trials
Whitehead, A. (2002) · doi:10.1002/0470854200 · Cited by 827
EULAR evidence-based recommendations for the management of fibromyalgia syndrome
Carville, S. F., Arendt-Nielsen, S., Bliddal, H., Blotman, F., Branco, J. C., Buskila, D., Da Silva, J. A. P., Danneskiold-Samsøe, B., Dincer, F., Henriksson, C., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.071522 · Cited by 752
Arnold, L. M., Rosen, A., Pritchett, Y. L., D'Souza, D. N., Goldstein, D. J., Iyengar, S., & Wernicke, J. F. (2005) · Pain · doi:10.1016/j.pain.2005.06.031 · Cited by 471
Bennett, R. M., Kamin, M., Karim, R., & Rosenthal, N. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(03)00116-5 · Cited by 403
Russell, J. I., Mease, P. J., Smith, T. R., Kajdasz, D. K., Wohlreich, M. M., Detke, M. J., Walker, D. J., Chappell, A. S., & Arnold, L. M. (2008) · Pain · doi:10.1016/j.pain.2008.02.024 · Cited by 367
Guidelines on the management of fibromyalgia syndrome – A systematic review
Häuser, W., Thieme, K., & Turk, D. C. (2010) · European Journal of Pain · doi:10.1016/j.ejpain.2009.01.006 · Cited by 347 · cited 1×
“Food and Drug Administration (FDA) for the management of fibromyalgia.(9) The objective for this study was to conduct a meta-analysis of the relative efficacy and safety of drugs that are licensed for or commonly used in the treatment of fibromyalgia.”
BackgroundHolman, A. J., & Myers, R. R. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21191 · Cited by 289
Arnold, L. M., Russell, I. J., Diri, E. W., Duan, W. R., Young, J. P., Sharma, U., Martin, S. A., Barrett, J. A., & Haig, G. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2008.03.013 · Cited by 277
Arnold, L. M., Hess, E. V., Hudson, J. I., Welge, J. A., Berno, S. E., & Keck, P. E. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)01089-0 · Cited by 261
A Double-blind Placebo Controlled Trial of Fluoxetine in Fibromyalgia
Wolfe, F., Cathey, M. A., & Hawley, D. J. (1994) · Scandinavian Journal of Rheumatology · doi:10.3109/03009749409103725 · Cited by 252
Cited by
EULAR revised recommendations for the management of fibromyalgia
Macfarlane, G. J., Kronisch, C., Dean, L. E., Atzeni, F., Häuser, W., Fluß, E., Choy, E., Kosek, E., Amris, K., Branco, J., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209724 · Cited by 1,566
Evaluation of inconsistency in networks of interventions
Veroniki, A. A., Vasiliadis, H. S., Higgins, J. P., & Salanti, G. (2013) · International Journal of Epidemiology · doi:10.1093/ije/dys222 · Cited by 576
Uncertainty in Treatment Rankings: Reanalysis of Network Meta-analyses of Randomized Trials
Trinquart, L., Attiche, N., Bafeta, A., Porcher, R., & Ravaud, P. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2521 · Cited by 202
Abraha, I., Cherubini, A., Cozzolino, F., De Florio, R., Luchetta, M. L., Rimland, J. M., Folletti, I., Marchesi, M., Germani, A., Orso, M., et al. (2015) · BMJ · doi:10.1136/bmj.h2445 · Cited by 165
Management of widespread pain and fibromyalgia
Whibley, D., Dean, L. E., & Basu, N. (2016) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-016-0056-5 · Cited by 23
Metadata
- Authors
- Roskell, N. S., Beard, S. M., Zhao, Y., & Le, T. K.
- Venue
- Pain Practice
- Publisher
- Wiley
- Published
- 2010-12-28
- Volume
- 11
- Issue
- 6
- Pages
- 516-527
- ISSN
- 1530-7085 (ISSN-L)
- 1533-2500
- OpenAlex
- W1582342156
- Cited by
- 49
- References
- 11
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.